Jaguar Health Inc. is a pharmaceutical company that focuses on the development and commercialization of novel plant-based medicines. The company was founded in 2013 and is headquartered in San Francisco, California. Jaguar Health is dedicated to addressing unmet medical needs and improving patient outcomes in areas such as gastrointestinal health and immune-related disorders.
One of the key areas of focus for Jaguar Health is the development of natural, plant-based medicines derived from botanical sources. The company utilizes its proprietary technologies and expertise to identify, extract, and develop therapeutic compounds from plants with medicinal properties. These compounds are then formulated into potential treatments for various medical conditions.
Jaguar Health has a diverse pipeline of products in different stages of development. One of its notable products is Mytesi® (crofelemer), an FDA-approved prescription medicine for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The company is also involved in the development of other potential therapeutics targeting various indications.
In 2015, Jaguar Health became a publicly-traded company through a reverse merger with a special purpose acquisition company (SPAC) called Concordia Pharmaceuticals Inc. Following the merger, Jaguar Health started trading on the NASDAQ stock exchange under the ticker symbol "JAGX." Going public allowed the company to access capital markets to support its research and development efforts, as well as its commercialization strategies.
As a pharmaceutical company, Jaguar Health is dedicated to advancing the field of plant-based medicine and bringing innovative therapies to patients in need. Through its research, development, and commercialization activities, the company aims to make a meaningful impact on the lives of individuals suffering from gastrointestinal and immune-related disorders.